Skip to content
This website uses cookies to help us understand the way visitors use our website. We can't identify you with them and we don't share the data with anyone else. If you click Reject we will set a single cookie to remember your preference. Find out more in our privacy policy.

Pioneering new treatments

We provide end-to-end translation of advanced therapies through access to extensive translational infrastructure, encompassing our NIHR BRCs, close links with our Clinical Research Network (CRN) and IQVIA Prime site (80 commercial trials set up within UCLPartners since inception), and integrated working with our AHSN (Academic Health Science Partnership). Our AHSC participates in more than 60% of the UK’s advanced therapy trials (

Our capabilities enable us to horizon-scan our extensive portfolio, validate with pre-clinical and clinical proof-of-concept studies, and collaborate with NHS and industry partners to bring forward novel and transformative therapies.

Through integrated working with our AHSN, we are building skills and knowledge in NHS-adoption strategies at the earliest stages of clinical development, so that the AHSC can act as an innovation pipeline to our AHSN, extending across North-Central and North East London, Essex, Beds and Herts.

Find out more: